Pharmaceutical practice for one case of central nervous system infection caused by <italic style="font-style: italic">Mycobacterium malmoense</italic> combined with drug-induced liver injury

LAI Shu; RUAN Yi; HE Yao

doi:10.6039/j.issn.1001-0408.2023.16.18

您当前的位置：

首页 >

文章列表页 >

Pharmaceutical practice for one case of central nervous system infection caused by Mycobacterium malmoense combined with drug-induced liver injury

更新时间：2023-08-24

- Pharmaceutical practice for one case of central nervous system infection caused by Mycobacterium malmoense combined with drug-induced liver injury
- ZHONGGUO YAOFANG Vol. 34, Issue 16, Pages: 2014-2017(2023)
- 作者机构：
  
  1.重庆市九龙坡区人民医院药剂科，重庆　400050
  2.重庆大学附属中心医院药剂科，重庆　400014
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.16.18
  CLC： R969.3;R378.91
- Published：30 August 2023，
  
  Received：03 February 2023，
  
  Revised：26 June 2023，
扫描看全文
赖舒,阮一,何瑶.1例玛尔摩分枝杆菌致中枢神经系统感染合并药物性肝损伤的药学实践 ^Δ[J].中国药房,2023,34(16):2014-2017.

LAI Shu,RUAN Yi,HE Yao.Pharmaceutical practice for one case of central nervous system infection caused by Mycobacterium malmoense combined with drug-induced liver injury[J].ZHONGGUO YAOFANG,2023,34(16):2014-2017.
赖舒,阮一,何瑶.1例玛尔摩分枝杆菌致中枢神经系统感染合并药物性肝损伤的药学实践 ^Δ[J].中国药房,2023,34(16):2014-2017. DOI： 10.6039/j.issn.1001-0408.2023.16.18.

LAI Shu,RUAN Yi,HE Yao.Pharmaceutical practice for one case of central nervous system infection caused by Mycobacterium malmoense combined with drug-induced liver injury[J].ZHONGGUO YAOFANG,2023,34(16):2014-2017. DOI： 10.6039/j.issn.1001-0408.2023.16.18.

摘要

目的

介绍1例玛尔摩分枝杆菌致中枢神经系统感染合并药物性肝损伤患者的药物诊疗方案和相关药学监护，为临床药师开展药学实践提供借鉴。

方法

临床药师参与1例玛尔摩分枝杆菌致中枢神经系统感染合并药物性肝损伤患者的治疗过程。考虑到患者头痛加剧，皮肤再次出现红斑，临床药师建议停用异烟肼，将治疗方案调整为利福平胶囊+盐酸乙胺丁醇片+硫酸阿米卡星注射液+克拉霉素片四联抗感染，并建议送脑脊液样本行二代基因测序以明确病原菌；待确认病原菌为玛尔摩分枝杆菌后，临床药师建议维持上述四联方案治疗；当患者出现药物性肝损伤后，临床药师协助医师调整用药方案，以盐酸莫西沙星片替代利福平胶囊，予谷胱甘肽片保肝治疗，并行肝肾功能、心电图监测。

结果与结论

医师采纳临床药师的建议；患者病情好转，准予出院。临床药师通过追踪患者的病史和用药史，查阅指南/共识、研究报道等文献资料，结合患者病情和药物作用特点，分析不良反应发生原因，及时调整抗感染药物治疗方案并针对不良反应进行对症处理，从药学角度协助医师完善了临床治疗决策，保证了临床用药的有效性、安全性。

Abstract

OBJECTIVE

To introduce the drug diagnosis， treatment plan and pharmaceutical care of a case of central nervous system infection caused by

Mycobacterium malmoense

combined with drug-induced liver injury， and to provide a reference for clinical pharmacists to carry out pharmaceutical practice.

METHODS

Clinical pharmacists participated in the whole treatment of a case of central nervous system infection caused by

M. malmoense

combined with drug-induced liver injury. Considering the patient’s headache worsened and the skin appeared red spot again， clinical pharmacists suggested stopping isoniazid and adjusted the quadruple anti-infection regimen to Rifampicin capsules+Ethambutol hydrochloride tablets+Amikacin sulfate injection+Clarithromycin tablets， and sending cerebrospinal fluid samples for the next-generation sequencing to identify the pathogen. After the pathogen was identified as

M. malmoense

， clinical pharmacists recommend continuing the above quadruple regimen. When the patient suffered from drug-induced liver injury， clinical pharmacists assisted physicians to adjust the medication plan， and suggested that Rifampicin capsules should be discontinued， Moxifloxacin hydrochloride tablets should be used for anti-infection treatment， Glutathione tablets should be used for liver protection treatment， and renal function and electrocardiogram monitoring should be performed.

RESULTS &CONCLUSIONS

The physicians adopted the advice of clinical pharmacists， and the patient was discharged after the condition improved. Clinical pharmacists review the patient’s medical and medication history， consult guidelines/consensus， research reports， and other literature materials， analyze the causes of adverse reactions based on the patient’s condition and the characteristics of drug action， adjust the medication plan of anti-infective drugs in a timely manner， and provide targeted treatment for adverse reactions. From a pharmaceutical perspective， they assist physicians in improving clinical treatment decisions and ensuring the efficacy and safety of clinical medication.

关键词

玛尔摩分枝杆菌中枢神经系统感染药物性肝损伤临床药师药学实践

Keywords

central nervous system infectiondrug-induced liver injuryclinical phama-cistspharmaceutical practice

references

中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南：2020年版[J]. 中华结核和呼吸杂志，2020，43（11）：918-946.

FURUUCHI K，MORIMOTO K，YOSHIYAMA T，et al. Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary di-sease and tuberculosis in a referral hospital in Japan[J]. Respir Med，2019，152：74-80.

LU M M，SADDI V，BRITTON P N，et al. Disease caused by non-tuberculous mycobacteria in children with cystic fibrosis[J]. Paediatr Respir Rev，2019，29：42-52.

ZHOU Y C，MU W，ZHANG J H，et al. Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006-2021：a systematic review and meta-analysis[J]. BMJ Open，2022，12（8）：e055672.

ADJEMIAN J，OLIVIER K N，PREVOTS D R. Epide-miology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States，2010-2014[J]. Ann Am Thorac Soc，2018，15（7）：817-826.

DALEY C L，IACCARINO J M，LANGE C，et al. Treatment of nontuberculous mycobacterial pulmonary disease：an official ATS/ERS/ESCMID/IDSA clinical practice guideline[J]. Eur Respir J，2020，56（1）：2000535.

KASPER D L，FAUCI A S. 哈里森感染病学[M]. 胡必杰，潘珏，高晓东，主译. 上海：上海科学技术出版社，2019：578-592.

LANGE C，BÖTTGER E C，CAMBAU E，et al. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases[J]. Lancet Infect Dis，2022，22（7）：e178-e190.

LANGE C，WAGNER D. Pulmonary disease caused by less common nontuberculous mycobacteria：new international guidelines[J]. Dtsch Med Wochenschr，2022，147（17）：1114-1121.

MAALOULY C，DEVRESSE A，MARTIN A，et al. Coinfection of Mycobacterium malmoense and Mycobacterium chimaera in a kidney transplant recipient：a case report and review of the literature[J]. Transpl Infect Dis，2020，22（2）：e13241.

HUANG M X，TAN Y J，ZHANG X X，et al. Effect of mixed infections with Mycobacterium tuberculosis and nontuberculous mycobacteria on diagnosis of multidrug-resistant tuberculosis：a retrospective multicentre study in China[J]. Infect Drug Resist，2022，15：157-166.

LEE E H，CHIN B，KIM Y K，et al. Clinical characte-ristics of nontuberculous mycobacterial disease in people living with HIV/AIDS in South Korea：a multi-center， retrospective study[J]. PLoS One，2022，17（11）：e0276484.

RYSKOVA L，BOLEHOVSKA R，KUKLA R，et al. Mycobacterioses induced by Mycobacterium abscessus：case studies indicating the importance of molecular analysis for the identification of antibiotic resistance[J]. Antibiotics，2022，11（7）：873.

中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南：2019年版[J].中华结核和呼吸杂志，2019，42（5）：343-355.

YAN M，BRODE S K，MARRAS T K. The other nontuberculous mycobacteria：clinical aspects of lung disease caused by less common slowly growing nontuberculous mycobacteria species[J]. Chest，2023，163（2）：281-291.

PRIETO L M，SANTIAGO B，DEL ROSAL T，et al. Linezolid-containing treatment regimens for tuberculosis in children[J]. Pediatr Infect Dis J，2019，38（3）：263-267.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

临床药师参与痛风性肾病合并肾性高血压患者治疗的药学实践

临床药师参与1例严重急性肾功能不全合并MRSA感染的药学实践

美国医院药学教育与实践

1例食管裂孔疝合并静脉导管感染患者的药学实践

5-氟尿嘧啶致中性粒细胞减少伴发热及化疗相关性腹泻的药学监护

Related Author

宋香清阎敏尹桃

余爱民姜赛平

Michael F.Powell 张伶俐全淑燕曾力楠王梦雅林芸竹

马丽萍?吝战权?朱建新?沈司京?

于芝颖?黄琳?顾群?冯婉玉?

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Pharmaceutical practice for one case of central nervous system infection caused by Mycobacterium malmoense combined with drug-induced liver injury

DOI：10.6039/j.issn.1001-0408.2023.16.18

摘要

Abstract

关键词

Keywords

references